Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Evommune, Inc. (NYSE:EVMN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $41.5556.

A number of research analysts have recently commented on EVMN shares. HC Wainwright restated a “neutral” rating on shares of Evommune in a research note on Monday, August 3rd. Raymond James Financial downgraded Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. Wall Street Zen cut shares of Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Royal Bank Of Canada reduced their price objective on shares of Evommune from $30.00 to $29.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings downgraded shares of Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th.

Get Evommune alerts:

Read Our Latest Analysis on Evommune

Insider Buying and Selling

In other news, insider Janice Drew sold 20,000 shares of Evommune stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.63, for a total value of $452,600.00. Following the completion of the transaction, the insider owned 67,794 shares in the company, valued at approximately $1,534,178.22. The trade was a 22.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur S. Kirsch purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were purchased at an average price of $13.30 per share, for a total transaction of $133,000.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at $133,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 28,926 shares of company stock valued at $654,997 over the last quarter. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Evommune

A number of large investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new stake in shares of Evommune during the second quarter valued at about $634,000. California State Teachers Retirement System lifted its holdings in shares of Evommune by 27,038.5% during the second quarter. California State Teachers Retirement System now owns 154,961 shares of the company’s stock worth $2,059,000 after purchasing an additional 154,390 shares during the period. Velan Capital Investment Management LP increased its holdings in Evommune by 1.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock worth $5,997,000 after buying an additional 5,000 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Evommune during the second quarter worth $340,000. Finally, Defilade Capital Management L.P. boosted its stake in shares of Evommune by 215.0% in the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after buying an additional 463,171 shares during the last quarter.

Evommune Stock Performance

Shares of EVMN stock opened at $13.20 on Wednesday. The firm has a market cap of $479.06 million and a P/E ratio of -1.20. Evommune has a fifty-two week low of $10.47 and a fifty-two week high of $33.20. The business’s 50 day moving average price is $12.83 and its 200-day moving average price is $19.82.

Evommune (NYSE:EVMN – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). As a group, equities analysts predict that Evommune will post -3.16 EPS for the current year.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

Featured Stories

• Five stocks we like better than Evommune
• Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
• Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
• Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
• Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.